Research programme: lipoxin A4 analogues - Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: lipoxin A4 analogues - Bayer HealthCare Pharmaceuticals

Alternative Names: Lipoxin A4 analog - Bayer HealthCare Pharmaceuticals; ZK-192

Latest Information Update: 19 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antiasthmatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare
  • 09 Nov 2005 Data presented at the 13th United European Gastroenterology Week (UEGW-2005) have been added to the Inflammatory bowel disorders pharmacodynamics section
  • 20 Nov 2004 Preclinical trials in Crohn's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top